| | | | | | | | | | |
|
|
| Dockets Entered
On December 2, 2004
Table of Contents
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
| 1991N-0384
|
| Nutrient Claims, Definitions of Terms, General Principles
|
|
|
| 1995S-0316
|
| 75-Day Premarket Notifications for New Dietary Ingredients
|
|
|
| 1996P-0418
|
| Reduce the Precense of Salmonella Enteritidis in Shell Eggs
|
|
|
| 1996P-0500
|
| Amend "Healthy" Definition re: Sodium Levels
|
|
|
| 1996V-0088
|
| Variance for Laser Light Show
|
|
|
| 1997P-0197
|
| Require that warning labels about risks of salmonella enteri
|
|
|
| 1998P-0203
|
| Eliminate Forced Molting of Laying Birds
|
|
|
| 2000N-0504
|
| Egg Safety Action Plan
|
|
|
| 2001P-0075
|
| Switch Status of Emergency Contraceptives from Rx to OTC
|
|
|
| 2002D-0018
|
| Race and Ethnicity Data in Clinical Trials for FDA
|
|
|
| 2002P-0413
|
| Health Claim: Phosphatidylserine and cognitive dysfunction
|
|
|
| 2003N-0059
|
| Pharmaceutical cGMPs for 21st Century: A Risk-Based Approach
|
|
|
| 2003N-0076
|
| Food Labeling: Trans Fatty Acids in Nutrition Labeling; Consumer research to consider possible footnote statements
|
|
|
| 2004D-0343
|
| Hospital Bed System Dimensional Guidance to Reduce Entrapment
|
|
|
| 2004D-0443
|
| Guidance for Industry on Quality Systems Approach to Pharmaceutical Current Good Manufacturing Regulations
|
|
|
| 2004N-0257
|
| Recordkeeping Requirements for Human Food and Cosmetics Manufactured from Processed With, or Otherwise Containing Meterial form Cattle
|
|
|
| 2004N-0267
|
| Applications for Approval to Market a New Drug; Complete Response Letter; Amendments to Unapproved Applications
|
|
|
| 2004P-0059
|
| Health Claim Petition: Glucosamine and Chondroitin Sulfate and Osteoarthritis
|
|
|
| 2004P-0386
|
| Reject New Drug Application 21-695
|
|
|
| 2004P-0411
|
| Compel Enforcement and Regulation of Amyl Nitrate
|
|
|
| 2004Q-0151
|
| Qualified Health Claim (QHC): soy protein and cancer
|
|
|
| 2004V-0155
|
| Valley Forge Composite Technologies Explosive Detection Systems
|
|
|
| 1991N-0384
|
| Nutrient Claims, Definitions of Terms, General Principles
|
|
| SUP 3
|
| ConAgra Foods, Inc.
|
| Vol #:
|
| 13
|
|
|
| 1995S-0316
|
| 75-Day Premarket Notifications for New Dietary Ingredients
|
|
|
| RPT
249
|
| Medical Research Institute
|
| Vol #:
|
| 181
|
|
|
| RPT
250
|
| Ztis Inc (SK Pharma Co. Ltd)
|
| Vol #:
|
| 182
|
|
|
| RPT
251
|
| American Research Institute of World Traditional Medicine
|
| Vol #:
|
| 183
|
|
|
| 1996P-0418
|
| Reduce the Precense of Salmonella Enteritidis in Shell Eggs
|
|
|
| C 842
|
| A. Kasper
|
| Vol #:
|
| 33
|
|
|
| C 843
|
| M. Romero
|
| Vol #:
|
| 33
|
|
|
| C 844
|
| L. Nissim
|
| Vol #:
|
| 33
|
|
|
| C
845
|
| Henningsen Food, Inc.
|
| Vol #:
|
| 33
|
|
|
| C 846
|
| S. Amy
|
| Vol #:
|
| 33
|
|
| | | | | | | | |
|
|
| EMC 11447
|
| B. Funck
|
| Vol #:
|
| 296
|
|
|
| EMC 11448
|
| M. Sobhy
|
| Vol #:
|
| 296
|
|
|
| EMC 11449
|
| T. Davis
|
| Vol #:
|
| 296
|
|
|
| EMC 11450
|
| L. Devitt
|
| Vol #:
|
| 296
|
|
|
| EMC 11451
|
| Ricarra j
|
| Vol #:
|
| 296
|
|
|
| EMC 11452
|
| J. Joh
|
| Vol #:
|
| 296
|
|
|
| 2002D-0018
|
| Race and Ethnicity Data in Clinical Trials for FDA
|
|
|
| EMC
3
|
| CDISC Submission Data Standards Team
|
| Vol #:
|
| 2
|
|
|
| EMC
4
|
| CDISC Submission Data Standards Team
|
| Vol #:
|
| 2
|
|
|
| 2002P-0413
|
| Health Claim: Phosphatidylserine and cognitive dysfunction
|
|
|
| LET
7
|
| HF-22
|
| Vol #:
|
| 6
|
|
|
| 2003N-0059
|
| Pharmaceutical cGMPs for 21st Century: A Risk-Based Approach
|
|
|
| C
5
|
| International Assn for Pharmaceutical Science and Technology (PDA)
|
| Vol #:
|
| 1
|
|
|
| C
6
|
| International Assn for Pharmaceutical Science and Technology (PDA)
|
| Vol #:
|
| 1
|
|
|
| 2003N-0076
|
| Food Labeling: Trans Fatty Acids in Nutrition Labeling; Consumer research to consider possible footnote statements
|
|
|
| EMC 472
|
| P. Cannin
|
| Vol #:
|
| 9
|
|
|
| EMC 473
|
| A. Richter
|
| Vol #:
|
| 9
|
|
|
| EMC 474
|
| J. Haffner
|
| Vol #:
|
| 9
|
|
|
| EMC 475
|
| D. Smith
|
| Vol #:
|
| 9
|
|
|
| EMC 476
|
| No signature
|
| Vol #:
|
| 9
|
|
|
| 2004D-0343
|
| Hospital Bed System Dimensional Guidance to Reduce Entrapment
|
|
|
| EMC
2
|
| AOPHA Health Committee
|
| Vol #:
|
| 1
|
|
|
| EMC
3
|
| Indiana Medical Device Manufacturers Council (IMDMC)
|
| Vol #:
|
| 1
|
|
|
| 2004D-0443
|
| Guidance for Industry on Quality Systems Approach to Pharmaceutical Current Good Manufacturing Regulations
|
|
|
| EMC
2
|
| Facility automation Management engineering (FAME) Systems
|
| Vol #:
|
| 1
|
|
|
| 2004N-0257
|
| Recordkeeping Requirements for Human Food and Cosmetics Manufactured from Processed With, or Otherwise Containing Meterial form Cattle
|
|
|
| EMC 20
|
| H. Qutub
|
| Vol #:
|
| 3
|
|
|
| EMC 21
|
| H. Qutub
|
| Vol #:
|
| 3
|
|
|
| 2004N-0267
|
| Applications for Approval to Market a New Drug; Complete Response Letter; Amendments to Unapproved Applications
|
|
|
| EMC 5
|
| H. Qutub
|
| Vol #:
|
| 1
|
|
|
| EMC 6
|
| H. Qutub
|
| Vol #:
|
| 1
|
|
|
| 2004P-0059
|
| Health Claim Petition: Glucosamine and Chondroitin Sulfate and Osteoarthritis
|
|
| | | | | | | | |
|
|
| LET
11
|
| HF-22
|
| Vol #:
|
| 13
|
|
|
| 2004P-0386
|
| Reject New Drug Application 21-695
|
|
|
| PDN
1
|
| HFD-7 TO Arnold & Porter LLP
|
| Vol #:
|
| 1
|
|
|
| 2004P-0411
|
| Compel Enforcement and Regulation of Amyl Nitrate
|
|
|
| EMC
5
|
| Committee to Monitor Poppers
|
| Vol #:
|
| 1
|
|
|
| EMC
6
|
| Committee to Monitor Poppers
|
| Vol #:
|
| 1
|
|
|
| 2004Q-0151
|
| Qualified Health Claim (QHC): soy protein and cancer
|
|
|
| EMC 13
|
| Soy Information Service
|
| Vol #:
|
| 5
|
|
|
| EMC 14
|
| The Weston A. Price Foundation
|
| Vol #:
|
| 5
|
|
|
| EMC 15
|
| Soy Information Service
|
| Vol #:
|
| 5
|
|
|
| LET 3
|
| The Solae Company
|
| Vol #:
|
| 5
|
|
|
| 2004V-0155
|
| Valley Forge Composite Technologies Explosive Detection Systems
|
|
|
| SUP
1
|
| Valley Forge Composite Technologies
|
| Vol #:
|
| 1
|
|